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PTVadapt was generated by adding a margin of 5 mm to the 
residual tumour visible on the intermediate MRI images 
(GTVadapt). A simultaneous integrated boost of 3.0 Gy/fr 
was delivered to PTVadapt on the last 6 frs of RT until a total 
dose of 45.6 Gy in 18 frs. 
 
Results: From September 2009 to September 2015, 56 pts 
completed the preoperative treatment. Toxicity. No G4 
toxicity occurred. G3 toxicity was only gastrointestinal: 
diarrhoea in 9/56 pts (16%), and proctitis in 3/56 (5%). 
Diarrhoea started before the adaptive RT phase in all the 
cases. Treatment feasibility. Two pts interrupted 
radiotherapy after 7 and 13 fractions, respectively, the 
remaining pts (54/56=96%) completed the treatment; the 
median duration of RT was 25 days (22-36 days). 47/56 pts 
(84%) and 45/56 pts (80%) received the full dose of 
oxaliplatin and 5-FU, respectively: 18% of pts received 
moderately reduced doses (60%-90%), and only two pts (2%) 
received less than 60% of the planned dose. Responses. Two 
pts achieved clinical complete response (cCR) and refused 
surgery, 1 pt was lost, 1 pt had early distant progression. 
Fifty-two pts underwent surgery (49 R0, 3 R1). Fifteen pts 
(29%) had pathological complete response (pCR); 24/52 (46%) 
had Tumor Regression Grade 3 response: 14/52 (27%) and 
6/52 (12%) had ≤5%, and 6 -10% residual viable cells, 
respectively. Regarding the two patients with cCR who 
refused surgery, 1 pt is still in cCR after 69 months, 1 pt had 
local relapse and underwent transanal resection 1 year after 
the preoperative treatment. 
 
Conclusion: This study confirms that adaptive Radiotherapy 
with Tomotherapy concomitant with oxaliplatin based 
chemotherapy in the preoperative treatment of rectal cancer 
is feasible, has an acceptable G3 toxicity rate and a very 
encouraging tumour response rate. A further dose escalation 
to the PTVadapt could be feasible and could increase the pCR 
and/or cCR rates. 
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Purpose or Objective: To evaluate the contribution of 
components for intense multimodal local treatment to the 
most adverse loco-regional staging scenario of M0 rectal 
cancer. 
 
Material and Methods: From 1/00 to 12/13, 95 cT4NXM0 
patients were treated with radical intent. 54 completed 
preoperative intensified chemo-radiation (all had post-
resection intraoperative electron pelvic boost, IOERT). 
Adjuvant systemic chemotherapy was recommended 
considering individualized risk features. Incomplete and 
complete pre and intra-operative treatment cohorts were 
comparable in characteristics: male (44/55%); age >70 
(44/33%); PS 0 (46/62%); inferior segment (42/41%); grade 2 
(67/62%); cN+ (75/83%). 
 
Results: With a median follow-up time of 62 months overall, 
disease-free (DFS) and loco-regional relapse-free survival 
were superior in the cohort of complete intensification (75% 
vs 51%, p=0.009; 67% vs 54%, p=0.03; 77% vs 71%, p=0.01), 
respectively. IOERT significantly improved presacral control 
rates. Multivariate analysis indicated that uninvolved surgical 
margin and intense tumour regression grade assessed 
response, were protective for DFS. 
 
Conclusion: Multimodal preoperative approach contributed 
to remarkable cancer-control outcomes and survival in cT4M0 
rectal patients, if components of therapy are feasible to be 
maximized (including free surgical margins) and an intense 
pathological disease response is described. 
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Purpose or Objective: The utility of SCCAg as a marker for 
treatment response or relapse is unknown in anal cancer. 
 
Material and Methods: This is a retrospective analysis of 28 
patients in whom SCCAg serum level was increased prior to 
treatment (mean 6,4 ng/ml, range 1,6-19,6 ng/ml). In all 
patients, measurement of SCCAg was performed at baseline, 
after completion of chemoradiation and at each visit during 
follow-up (median 35 months, range 7-81). All patients were 
treated radically. 
 
Results: In 27 (96%) patients SCCAg level decreased to normal 
level after treatment. One remaining patient had persistent 
unreseceble tumor confirmed by pathology and persistent 
high SCCAg level. Only one of 27 patients with normalization 
of SCCAg after chemoradiation had persistent ulceration in 
the anal canal and persistent enlarger inguinal lymph node. 
This patient underwent abdominoperineal resection with 
inguinal lymphadenectomy. On pathological examination only 
a few cancer cells were found in the inguinal nodes and the 
primary tumour site was free of cancer.. In six patients, 
increase of SCCAg was observed during follow-up. In one of 
these 6 patients, locoregional recurrence was also detected 
clinically at the same time. In 4 patients, the diagnostic 
examinations performed because of elevated SCCAg reveled 
locoregional recurrence (n=2) or distant metastases (n=2). In 
one remaining patient the diagnostic examinations were 
negative; distant metastases were detected 5 months 
thereafter. The remaining 20 patients had both: sustained 
clinical complete regression and normal SCCAg level.  
 
Conclusion: This study suggests utility of SCCAg in the 
monitoring of response to chemoradiation and in the 
detection of recurrence 
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Purpose or Objective: Preoperative radiotherapy (RT), alone 
or in combination with chemotherapy (CT) is the standard of 
care in patients (pts) with locally advanced rectal cancer 
(LARC). Nevertheless in those tumors in which the down-
sizing and down-staging are necessary, (cT3 MRF - / + N0 of 
lower rectum or cT3-4 MRF + / N0-2) preoperative chemo-
radiotherapy (CT-RT) is recommended. There is a correlation 
between RT dose and response and the tumor regression 
grade (TRG) represents an independent prognostic factor. 
The aim of the study is to analyze the role of RT dose 
intensification in the preoperative treatment of LARC in 
terms of feasibility, toxicity and pathological response grade. 
 
Material and Methods: We have retrospectively analyzed 69 
pts with histological diagnosis of LARC (stage II-III) treated in 
five Italian Radiotherapy centres. The treatment programme 
included: intensity-modulated radiotherapy (IMRT) delivered 
